Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
iShares MBS ETF
MBB
$36.7B
| $418M | 0.1% |
4,393,430
-3,239,354
| -42% | -$309M |
2025 Q2
2 quarters
|
|
152
Boston Scientific
BSX
$62.7B
| $416M | 0.1% |
4,360,692
-159,259
| -4% | -$15.6M |
2013 Q2
50 quarters
|
|
153
Stryker
SYK
$105B
| $411M | 0.1% |
1,168,656
+239,750
| +26% | +$87.4M |
2013 Q2
50 quarters
|
|
154
Synopsys
SNPS
$94B
| $410M | 0.1% |
872,550
-144,635
| -14% | -$64.3M |
2013 Q2
50 quarters
|
|
155
Warner Bros
WBD
$77.6B
| $407M | 0.1% |
14,118,028
+2,792,774
| +25% | +$65.3M |
2013 Q2
50 quarters
|
|
156
AutoZone
AZO
$45.6B
| $406M | 0.1% |
119,662
-17,489
| -13% | -$66.1M |
2013 Q2
50 quarters
|
|
157
PUT
iShares MSCI EAFE ETF
EFA
$76B
| $405M | 0.1% |
4,221,100
+2,097,200
| +99% | +$199M |
2023 Q4
8 quarters
|
|
158
Blackrock
BLK
$165B
| $403M | 0.1% |
376,657
-50,296
| -12% | -$55M |
2013 Q2
50 quarters
|
|
159
J.M. Smucker
SJM
$12.4B
| $401M | 0.1% |
4,104,651
+145,594
| +4% | +$15.1M |
2013 Q2
50 quarters
|
|
160
Comcast
CMCSA
$77B
| $400M | 0.1% |
13,375,888
-1,168,781
| -8% | -$33.3M |
2013 Q2
50 quarters
|
|
161
Abbott
ABT
$167B
| $399M | 0.1% |
3,182,319
-892,146
| -22% | -$114M |
2013 Q2
50 quarters
|
|
162
Bristol-Myers Squibb
BMY
$126B
| $395M | 0.09% |
7,318,271
-1,818,809
| -20% | -$87.5M |
2013 Q2
50 quarters
|
|
163
Blackstone
BX
$84.3B
| $390M | 0.09% |
2,530,367
-254,415
| -9% | -$38.7M |
2022 Q1
15 quarters
|
|
164
Capital One
COF
$119B
| $389M | 0.09% |
1,604,750
+36,520
| +2% | +$8.13M |
2013 Q2
50 quarters
|
|
165
Vertex Pharmaceuticals
VRTX
$128B
| $384M | 0.09% |
847,758
+105,271
| +14% | +$45.4M |
2013 Q2
50 quarters
|
|
166
Southern Company
SO
$96B
| $383M | 0.09% |
4,391,064
+914,181
| +26% | +$83.5M |
2013 Q2
50 quarters
|
|
167
ASML
ASML
$695B
| $380M | 0.09% |
355,244
-72,536
| -17% | -$75.7M |
2013 Q2
50 quarters
|
|
168
AT&T
T
$167B
| $380M | 0.09% |
15,278,145
-6,949,251
| -31% | -$176M |
2013 Q2
50 quarters
|
|
169
Ferguson
FERG
$42.8B
| $379M | 0.09% |
1,703,509
-559,110
| -25% | -$134M |
2021 Q1
19 quarters
|
|
170
Mettler-Toledo International
MTD
$29.7B
| $377M | 0.09% |
270,717
-1,979
| -0.7% | -$2.76M |
2013 Q2
50 quarters
|
|
171
SPDR Gold Trust
GLD
$142B
| $374M | 0.09% |
943,871
-181,505
| -16% | -$69.3M |
2013 Q2
50 quarters
|
|
172
Cadence Design Systems
CDNS
$96.6B
| $372M | 0.09% |
1,189,058
-139,434
| -10% | -$45.5M |
2013 Q2
50 quarters
|
|
173
CME Group
CME
$95.3B
| $372M | 0.09% |
1,360,727
-162,218
| -11% | -$44.1M |
2013 Q2
50 quarters
|
|
174
Accenture
ACN
$130B
| $371M | 0.09% |
1,384,267
-283,468
| -17% | -$72M |
2013 Q4
48 quarters
|
|
175
S&P Global
SPGI
$114B
| $366M | 0.09% |
699,860
-112,621
| -14% | -$55.7M |
2016 Q2
38 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.